131 related articles for article (PubMed ID: 36067943)
1. Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion.
Andrés C; González-Sánchez A; Jiménez M; Márquez-Algaba E; Piñana M; Fernández-Naval C; Esperalba J; Saubi N; Quer J; Rando-Segura A; Miarons M; Codina MG; Ruiz-Camps I; Pumarola T; Abrisqueta P; Antón A
Clin Microbiol Infect; 2023 Feb; 29(2):240-246. PubMed ID: 36067943
[TBL] [Abstract][Full Text] [Related]
2. Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients.
Gliga S; Lübke N; Killer A; Gruell H; Walker A; Dilthey AT; Thielen A; Lohr C; Flaßhove C; Krieg S; Pereira JV; Seraphin TP; Zaufel A; Däumer M; Orth HM; Feldt T; Bode JG; Klein F; Timm J; Luedde T; Jensen BO
Clin Infect Dis; 2023 Feb; 76(3):408-415. PubMed ID: 36189631
[TBL] [Abstract][Full Text] [Related]
3. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
4. Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies.
Leducq V; Zafilaza K; Fauchois A; Ghidaoui E; Sayon S; Dorival C; Meledje ML; Lusivika-Nzinga C; Yordanov Y; Martin-Blondel G; Carrat F; Marcelin AG; Soulie C
J Infect Dis; 2024 May; 229(5):1341-1351. PubMed ID: 37996072
[TBL] [Abstract][Full Text] [Related]
5. Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2.
Hirotsu Y; Kobayashi H; Kakizaki Y; Saito A; Tsutsui T; Kawaguchi M; Shimamura S; Hata K; Hanawa S; Toyama J; Miyashita Y; Omata M
Med; 2023 Nov; 4(11):813-824.e4. PubMed ID: 37683636
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 evolution during prolonged infection in immunocompromised patients.
Marques AD; Graham-Wooten J; Fitzgerald AS; Sobel Leonard A; Cook EJ; Everett JK; Rodino KG; Moncla LH; Kelly BJ; Collman RG; Bushman FD
mBio; 2024 Mar; 15(3):e0011024. PubMed ID: 38364100
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
[TBL] [Abstract][Full Text] [Related]
8. Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab.
Palomino-Cabrera R; Tejerina F; Molero-Salinas A; Ferris M; Veintimilla C; Catalán P; Rodríguez Macias G; Alonso R; Muñoz P; García de Viedma D; Pérez-Lago L;
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0026623. PubMed ID: 37278655
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 spike codon mutations and risk of hospitalization after antispike monoclonal antibody therapy in solid organ transplant recipients.
Yetmar ZA; Yao JD; Razonable RR
J Med Virol; 2023 Jun; 95(6):e28885. PubMed ID: 37334976
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series.
Cicchitto G; Cardillo L; Sequino D; Sabatini P; Adamo L; Marchitiello R; Viscardi M; Cozzolino L; Cavallera A; Bocchino M; Sanduzzi Zamparelli A; Ferrigno F; de Carlo E; de Martinis C; Fusco G
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680143
[TBL] [Abstract][Full Text] [Related]
11. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
[TBL] [Abstract][Full Text] [Related]
12. Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant.
Huygens S; Oude Munnink B; Gharbharan A; Koopmans M; Rijnders B
Clin Infect Dis; 2023 Feb; 76(3):e507-e509. PubMed ID: 35867699
[TBL] [Abstract][Full Text] [Related]
13. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
Shah M; Woo HG
Front Immunol; 2021; 12():830527. PubMed ID: 35140714
[TBL] [Abstract][Full Text] [Related]
14. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
[TBL] [Abstract][Full Text] [Related]
15. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
[TBL] [Abstract][Full Text] [Related]
16. Delta-Omicron recombinant escapes therapeutic antibody neutralization.
Duerr R; Zhou H; Tada T; Dimartino D; Marier C; Zappile P; Wang G; Plitnick J; Griesemer SB; Girardin R; Machowski J; Bialosuknia S; Lasek-Nesselquist E; Hong SL; Baele G; Dittmann M; Ortigoza MB; Prasad PJ; McDonough K; Landau NR; George KS; Heguy A
bioRxiv; 2022 Aug; ():. PubMed ID: 35411351
[TBL] [Abstract][Full Text] [Related]
17. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
[TBL] [Abstract][Full Text] [Related]
18. Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments.
Gupta A; Konnova A; Smet M; Berkell M; Savoldi A; Morra M; Van Averbeke V; De Winter FH; Peserico D; Danese E; Hotterbeekx A; Righi E; ; De Nardo P; Tacconelli E; Malhotra-Kumar S; Kumar-Singh S
J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36727404
[TBL] [Abstract][Full Text] [Related]
19. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.
Bronstein Y; Adler A; Katash H; Halutz O; Herishanu Y; Levytskyi K
J Med Virol; 2022 Mar; 94(3):1241-1245. PubMed ID: 34755363
[TBL] [Abstract][Full Text] [Related]
20. De novo emergence of SARS-CoV-2 spike mutations in immunosuppressed patients.
Simons LM; Ozer EA; Gambut S; Dean TJ; Zhang L; Bhimalli P; Schneider JR; Mamede JI; Ison MG; Karmali R; Gordon LI; Lorenzo-Redondo R; Hultquist JF
Transpl Infect Dis; 2022 Dec; 24(6):e13914. PubMed ID: 35899968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
